This article is more than 5 years old. Information may no longer be current.
Aflibercept conversion yields stabilized vision, improved anatomic outcomes for neovascular AMD
Click Here to Manage Email Alerts
Converting to aflibercept yielded stabilized vision and improved anatomic outcomes and enabled slightly extended injection intervals in patients with refractory or recurrent neovascular age-related macular degeneration, according to a study.
The retrospective chart review comprised 102 eyes of 94 patients with neovascular AMD; 68 cases were categorized as refractory and 34 were categorized as recurrent.
Eyes were previously treated with a mean of 20.4 injections of Avastin (bevacizumab, Genentech) or Lucentis (ranibizumab, Genentech) and a mean of 3.8 injections of Eylea (aflibercept, Regeneron).
Mean visual acuity remained stable in all groups after one aflibercept injection. Central macular thickness significantly diminished in all groups after one injection and after the final injection (P < .001 for both).
Intraretinal and subretinal fluid significantly decreased after one injection in the refractory group (P < .001 for both) and the mean injection interval increased from 5.2 weeks to 6.2 weeks, which was considered statistically significant (P = .003).
Within the recurrent group, intraretinal and subretinal fluid significantly decreased after one injection (P = .003, P = .046, respectively). The mean injection interval increased from 7.2 to 9.5 weeks, which was also statistically significant (P = .001).
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.
Click Here to Manage Email Alerts